11/21
08:05 am
rgnx
REGENXBIO Inc. (NASDAQ: RGNX) had its price target lowered by analysts at HC Wainwright from $40.00 to $36.00. They now have a "buy" rating on the stock.
Medium
Report
REGENXBIO Inc. (NASDAQ: RGNX) had its price target lowered by analysts at HC Wainwright from $40.00 to $36.00. They now have a "buy" rating on the stock.
11/20
08:07 am
rgnx
REGENXBIO Inc. (NASDAQ: RGNX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $52.00 price target on the stock.
Low
Report
REGENXBIO Inc. (NASDAQ: RGNX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $52.00 price target on the stock.
11/18
07:08 am
rgnx
REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA [Yahoo! Finance]
Medium
Report
REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA [Yahoo! Finance]
11/18
07:05 am
rgnx
REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA
Low
Report
REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA
11/15
08:03 am
rgnx
REGENXBIO Inc. (NASDAQ: RGNX) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $22.00 price target on the stock.
High
Report
REGENXBIO Inc. (NASDAQ: RGNX) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $22.00 price target on the stock.
11/14
07:07 am
rgnx
REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202 [Yahoo! Finance]
High
Report
REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202 [Yahoo! Finance]
11/14
07:05 am
rgnx
REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202
High
Report
REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202
11/9
09:28 am
rgnx
Analysts Have Made A Financial Statement On REGENXBIO Inc.'s (NASDAQ:RGNX) Third-Quarter Report [Yahoo! Finance]
Low
Report
Analysts Have Made A Financial Statement On REGENXBIO Inc.'s (NASDAQ:RGNX) Third-Quarter Report [Yahoo! Finance]
11/7
04:11 pm
rgnx
REGENXBIO Inc. (NASDAQ: RGNX) had its price target raised by analysts at HC Wainwright from $39.00 to $40.00. They now have a "buy" rating on the stock.
Low
Report
REGENXBIO Inc. (NASDAQ: RGNX) had its price target raised by analysts at HC Wainwright from $39.00 to $40.00. They now have a "buy" rating on the stock.
11/7
02:31 am
rgnx
Regenxbio Inc (RGNX) Q3 2024 Earnings Call Highlights: Advancements in Gene Therapy and ... [Yahoo! Finance]
High
Report
Regenxbio Inc (RGNX) Q3 2024 Earnings Call Highlights: Advancements in Gene Therapy and ... [Yahoo! Finance]
11/6
04:05 pm
rgnx
REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates
High
Report
REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates
11/5
08:04 am
rgnx
Regenxbio Inc (RGNX) Q3 2024: Everything You Need To Know Ahead Of Earnings [Yahoo! Finance]
Low
Report
Regenxbio Inc (RGNX) Q3 2024: Everything You Need To Know Ahead Of Earnings [Yahoo! Finance]
11/4
07:05 am
rgnx
REGENXBIO to Participate in Upcoming Investor Conferences
Low
Report
REGENXBIO to Participate in Upcoming Investor Conferences
10/30
07:05 am
rgnx
REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational Highlights
Medium
Report
REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational Highlights
10/23
10:04 am
rgnx
The past five years for REGENXBIO (NASDAQ:RGNX) investors has not been profitable [Yahoo! Finance]
Low
Report
The past five years for REGENXBIO (NASDAQ:RGNX) investors has not been profitable [Yahoo! Finance]
10/22
08:32 am
rgnx
REGENXBIO Inc. (NASDAQ: RGNX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $52.00 price target on the stock.
Medium
Report
REGENXBIO Inc. (NASDAQ: RGNX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $52.00 price target on the stock.
10/21
07:20 am
rgnx
REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024 [Yahoo! Finance]
High
Report
REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024 [Yahoo! Finance]
10/21
07:05 am
rgnx
REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024
Medium
Report
REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024
10/18
07:05 am
rgnx
REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting
Low
Report
REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting
10/10
09:36 am
rgnx
REGENXBIO Inc. (NASDAQ: RGNX) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $18.00 price target on the stock.
Low
Report
REGENXBIO Inc. (NASDAQ: RGNX) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $18.00 price target on the stock.
10/1
07:24 am
rgnx
Tagworks Pharmaceuticals Appoints Ken Mills as Chief Executive Officer [Yahoo! Finance]
Medium
Report
Tagworks Pharmaceuticals Appoints Ken Mills as Chief Executive Officer [Yahoo! Finance]
9/23
04:05 pm
rgnx
REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines Conference
Medium
Report
REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines Conference
9/20
02:37 am
rgnx
REGENXBIO Inc. (NASDAQ: RGNX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
High
Report
REGENXBIO Inc. (NASDAQ: RGNX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
9/17
07:10 am
rgnx
REGENXBIO Appoints Mitchell Chan as Chief Financial Officer [Yahoo! Finance]
Low
Report
REGENXBIO Appoints Mitchell Chan as Chief Financial Officer [Yahoo! Finance]
9/17
07:05 am
rgnx
REGENXBIO Appoints Mitchell Chan as Chief Financial Officer
Low
Report
REGENXBIO Appoints Mitchell Chan as Chief Financial Officer